Kodiak Sciences Inc., a biotechnology company focused on retinal therapeutics, has announced that it will present its pipeline programs targeting glaucoma at the American Chemical Society $(ACS.AU)$ Fall 2025 Meeting. The presentation, scheduled for August 19, 2025, will be delivered by Dr. Dolly S. Chang, the Chief Scientific Officer of Kodiak Sciences. The presentation, titled "Unmet clinical endpoints and therapeutics for retinal diseases: Challenges and innovations," will explore the company's advancements, particularly in dual-mechanism therapies aimed at glaucoma optic neuropathy. Kodiak Sciences is employing its Antibody Biopolymer Conjugate Drug (ABCD) platform to develop a treatment combining a novel small-molecule NLRP3 inhibitor with an intraocular pressure-lowering agent. The treatment is designed for quarterly intravitreal injections. The results of these advancements will be shared during the symposium "EyeNovation: Small Molecule Drug Discovery for Common Ocular Diseases." Slides of the presentation will be available on Kodiak's website following the event.